Comparative molecular field analysis (CoMFA) for p38 inhibitors

Internet Electronic Journal of Molecular Design

Volumn 6, Issue 12, 2007, Pages 385-395

  Nayana, Munuganti Ravi Shashi ^a   Sekhar, Yadavalli Nataraja ^a  

^a OSMANIA UNIVERSITY   (India)

Author keywords

Benzimidazolone derivatives; CoMFA; Comparative molecular field analysis; p38 kinase; QSAR; Quantitative structure activity relationships

Indexed keywords

EID: 38149035208     PISSN: None     EISSN: 15386414     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. E. Chen, E.C. Keystone, E.N. Fish, Restricted cytokine expression in rheumatoid arthritis, Arthritis. Rheum. 1993, 36, 901-910.
2. T. Pincus, Long-term outcomes in rheumatoid arthritis, Br. J. Rheumatol. 1995, 34, 59-73.
3. A.H. Julianne, K. Florida D.R. Rowena J.S. Peter, Ida Ita, X.M. Sherrie V.P. James, E.C.A. Cornelis Hop; K. Sanjeev, W. Zhen J.O. Stephen, A.O Edward, P. Gene, E.T. James, W. Andrew, M.Z. Dennis, B.D. James, p38 Inhibitors: piperidine-and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones, Bioorg. Med. Chem. Lett. 2003, 13, 467.
4. A.D. Mark, A.L. Michael, F.M.C. Kim, T.B. John, J.C. Thomas, R.C. Santo, C. Csilla, J.D. Alan, C.E. Nancy, A.G. Christopher, K.J. Crystal, M.L. Jeff, H.M. William, M.P. Kevin, A.S. Ingrid, S. Linne, J.S. Francis, H.Y. Chul, Benzimidazolone p38 inhibitors, Bioorg. Med. Chem. Lett. 2004, 14, 919-923.
5. J.L. Adams, A.T. Badger, S. Kumar, J.C. Lee, A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinones p38 kinase inhibitors, Prog. Med. Chem. 2001, 38, 1.
6. S. Kumar, P.C. McDonnell, R.J. Gum, A.T. Hand, J.C. Lee, P.R. Young, Novel homologues of CSBP/p38MAP Kinase: Activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles, Biochem. Biophys. Res. Commun. 1997, 235, 533.
7. J. Harada, M. Sugimoto, An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons, Japan. J. Pharmacol. 1999, 79, 369-378.
8. R. Laszlo, E.D. Franco, B. Thomas, F. Roland, G. Hermann, H. Pete, M. Ute, W. Romain, G.Z. Alfred, SAR of 2,6-diamino-3, 5-difluoropyridinyl substituted heterocycles as novel p38 MAP kinase inhibitors, Bioorg. Med. Chem. Lett. 2002, 12, 2109.
9. S. M. Vadlamudi, V. M. Kulkarni, 3D-QSAR of Protein Tyrosine Phosphatase 1B Inhibitors by Genetic Function Approximation, Internet Electron. J. Mol. Des. 2004, 3, 586-609.
10. O. Ivanciuc, 3D QSAR Models. In: QSPR/QSAR Studies by Molecular Descriptors. Ed.: M. V. Diudea. Nova Science, Huntington, N.Y., 2001, pp. 233-280.
11. http://www.coepra.org.
12. SYBYL, version 6.8; Tripos Associates: St. Louis, MO, 2000.
13. J. Gasteiger, M. Marsilli, Iterative partial equalization of orbital electro negativity - a rapid access to atomic charges, Tetrahedron. 1980, 36, 3219.
14. J. J. J. Stewart, MOPAC: A semi empirical molecular orbital program, Comput. Aided Mol. Des. 1990, 4, 1.
15. P. Geladi, Notes on the history and nature of partial least squares (PLS) modeling, J. Chemon. 1998, 2, 231.
16. R. Cramer III, D. Bunce, D.E., Patterson, I.E. Frank, Cross validation, bootstrapping, and partial least squares compared with multiple regression Conventional. QSAR. Quant. Struct. Act. Relat. 1988, 7, 18-25.
17. C.M. Venkatachalam, X. Jiang, T. Oldfield, M. Waldman, LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites, J. Mol. Graph. Model. 2003, 21, 289-307.
18. E.Perola, Minimizing False Positives in Kinase Virtual Screens, Proteins, 2006, 64, 422-435.